NCT02156570View on ClinicalTrials.gov

DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

December 31, 2017

Conditions
Hepatitis C
Interventions
DRUG

Sofosbuvir and ribavirin

Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg \<75kg, 1200mg \>/= 75 kg) Treatment will be for 6 weeks in all participants.

Trial Locations (5)

1023

Auckland City Hospital, Auckland

2010

St Vincent's Hospital, Sydney

3004

Alfred Hospital, Melbourne

3050

Royal Melbourne Hospital, Melbourne

5000

Royal Adelaide Hospital, Adelaide

Sponsors

Lead Sponsor

Kirby Institute
All Listed Sponsors
lead

Kirby Institute

OTHER_GOV

NCT02156570 - DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) | Biotech Hunter | Biotech Hunter